A Trial to Learn if Dupilumab is Safe for and Helps Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis

Recruiting

Phase 2

Phase 3

DupilumabA Trial to Learn if Dupilumab is Safe for and Helps Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis

Sponsor:

Regeneron Pharmaceuticals

Code:

NCT05831176

Conditions

Eosinophilic Gastritis

Eosinophilic Duodenitis

Eosinophilic Gastrointestinal Disease

Eligibility Criteria

Sex: All

Age: 12+

Healthy Volunteers: Not accepted

Interventions

Dupilumab Dose 1

Dupilumab Dose 2

Matching Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-31. This information was provided to ClinicalTrials.gov by Regeneron Pharmaceuticals on 2025-03-25.